Skip to main content

UR Medicine

menu
UR Medicine / Dermatology / News

 

News

20242023202220212020

Scientists Developing Microchips with Brain and Lung Tissue to Study Viral Neuroinflammation

Wednesday, October 16, 2024

Researchers will use tissue-on-chip technology as a new way to explore the relationship between the lungs and brain. Scientists are developing advanced tools to understand and treat neurological symptoms such as brain fog associated with respiratory diseases like influenza. The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS), awarded a three-year contract to researchers at the University of Rochester to develop a technology to model respiratory disease effects on the brain and test therapeutic drugs to prevent and treat symptoms. The base-year is funded at $2.4 million with two option years which, if fully funded, would total $7.1 million.

Read More: Scientists Developing Microchips with Brain and Lung Tissue to Study Viral Neuroinflammation

Remembering the Life of a True Giant of Dermatology

Monday, July 15, 2024

Lowell Goldsmith, MD, whose boundless curiosity led him to international renown as a dermatology expert who could achieve the near impossible, passed away in North Carolina on July 10. He was 86. Dr. Goldsmith was founding chair of the Department of Dermatology at the University of Rochester Medical Center, former acting chair of Medicine, and dean of the School of Medicine and Dentistry, where he brought a spark of entrepreneurship and commitment to patients. He did it all with a warmth and sense of humor that colleagues say helped inspire the people around him.

Read More: Remembering the Life of a True Giant of Dermatology

New NIH-funded Center Could Soon Reduce the Need for Pharmaceutical Trials on Animals

Tuesday, January 9, 2024

Rochester is one of four NIH-sponsored centers that aims to produce tissue-on-chip devices as FDA-qualified drug development tools. The center aims to develop five Food and Drug Administration–qualified drug development tools related to study barrier functions in disease—interfaces in tissue that are critical for the progression of infection, cancer, and many autoimmune disorders.

Read More: New NIH-funded Center Could Soon Reduce the Need for Pharmaceutical Trials on Animals

Best Eczema Treatments for Winter

Thursday, January 4, 2024

The cold, dry air and indoor heating can wreak havoc on sensitive skin, especially for those with hand or facial eczema. Lisa Beck, M.D., professor of Dermatology and eczema specialist, shares a few tips for eczema patients looking to keep the winter woes at bay.

Read More: Best Eczema Treatments for Winter